Skip to main content
Caplight Logo









Excision BioTherapeutics

Excision BioTherapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://excision.bio

Last Round

Grant

Sep 29, 2022

Total Funding Raised

$76.85M

Company Overview

Excision BioTherapeutics is a biotechnology company developing CRISPR-based gene editing therapeutics to cure viral infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyCRISPRgene editingCRISPR therapeuticsviral cureHIV curein vivo therapynuclease technologybiotechnologyclinical-stage biotechgenomic medicineprecision medicineDNA excisiongenetic engineeringdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Excision BioTherapeutics Comparables

Compare Excision BioTherapeutics with similar companies based on industry and business-model similarity.

Excision BioTherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
American Gene Technologies
84%
Shanghai Bendao Gene Technology
77%
Intellia Therapeutics
75%

Excision BioTherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 29, 2022
Series AFeb 17, 2021
SeedSep 6, 2017

Excision BioTherapeutics Investors

Notable investors and investment history

Excision BioTherapeutics investors
InvestorRounds
GreatPoint VenturesSeries A
Cota CapitalSeries A
GaingelsSeries A
GreatPoint VenturesSeries A
WRVI CapitalSeries A
ARTIS VenturesSeries A, Seed
BiovergeSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 17, 2025

    Presented data at the ICE-HBV Hepatitis B Cure Symposium.

  • Sep 17, 2025

    EBT-107 program shows safety and potency for hepatitis B treatment.

Excision BioTherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Excision BioTherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Excision BioTherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range25
Year Founded2015
Last FundingSep 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?